Prostacyclin for pulmonary arterial hypertension - Barnes, H - 2019 | Cochrane Library Skip to
Content Cookies Our site uses cookies to improve your experience. You can find out more …

Introduction The most grievous complication of the COVID-19 is the acute respiratory
distress syndrome. A specific, rescue treatment for rapidly deteriorating patients should …

Pediatric pulmonary hypertension (PAH) is a rare disease that carries a poor prognosis if left
untreated. Although there are published guidelines for the treatment of children with …

Pulmonary arterial hypertension (PAH) is a rare, complex, and deadly cardiopulmonary
disease. It is characterized by changes in endothelial cell function and smooth muscle cell …

Pulmonary arterial hypertension (PAH) is a rare and grave disease that affects the lungs and
heart. 1, 2 The primary goal of treatment is to delay disease progression, and as such …

Pregnancy in patients with pulmonary artery hypertension (PAH) is associated with high
mortality and morbidity. Despite the risks, more patients with PAH are becoming pregnant …

The carboxylesterase drug hydrolysis pathway has been used extensively to improve the
oral availability of drugs under the assumption that the high capacity and low substrate …

Intravenous (iv) prostacyclin is the cornerstone treatment in high‐risk pulmonary arterial
hypertension (PAH) patients. Selexipag is an orally available prostacyclin receptor agonist …

Pulmonary hypertension (PH) is a syndrome characterized by elevated pressures in the
pulmonary circulation resulting from a variety of conditions, as defined by the World Health …

Background: The etiology of pulmonary arterial hypertension associated with congenital
heart disease (PAHCHD) is complicated and the phenotype is heterogeneous. Genetic …